LTGO Insider Trading Activity and SEC Form 4 Filings
LTGO insider trading summary
Over the past 12 months, insiders at Latigo Biotherapeutics, Inc. (LTGO) reported 7 open-market purchases worth $17.6M by 7 insiders and no sales on SEC Form 4. Net insider buying was $17.6M.
Latest LTGO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 10, 2026 | James B. Tananbaum | Insider | Buy | $2.5M (140,000 @ $18.00) |
| Aug 10, 2026 | Foresite Capital Fund V, L.P. | 10% Owner | Buy | $2.5M (140,000 @ $18.00) |
| Aug 10, 2026 | Foresite Capital Opportunity Management V, LLC | 10% Owner | Buy | $2.5M (140,000 @ $18.00) |
| Aug 10, 2026 | Foresite Capital Opportunity Fund V, L.P. | 10% Owner | Buy | $2.5M (140,000 @ $18.00) |
| Aug 10, 2026 | Foresite Capital Management VI LLC | 10% Owner | Buy | $2.5M (140,000 @ $18.00) |
| Aug 10, 2026 | Foresite Capital Fund VI LP | 10% Owner | Buy | $2.5M (140,000 @ $18.00) |
| Aug 10, 2026 | Foresite Capital Management V, LLC | 10% Owner | Buy | $2.5M (140,000 @ $18.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.